Results 61 to 70 of about 6,034 (173)

Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis

Breast Cancer Research, 2018
Background Metastatic triple-negative breast cancer (TNBC) is a heterogeneous and incurable disease. Numerous studies have been conducted to seek molecular targets to treat TNBC effectively, but chemotherapy is still the main choice for patients with ...
Kideok Jin, Niranjan B. Pandey, Aleksander S. Popel   +2 more
doaj   +1 more source

Maraviroc and raltegravir [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

Drug Design, Development and Therapy, 2016
Alejandro Gonzalez-Serna,1 Miguel Genebat,2 Ezequiel Ruiz-Mateos,2 Manuel Leal2 1Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Maranon, Madrid, 2Laboratory of Immunovirology, Institute of Biomedicine of Seville, Seville,
Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M   +3 more
doaj  

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study

Microbiology Spectrum
The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic ...
Ségolène Gracias, Ikrame El Yaalaoui, Benoît Visseaux, Charlotte Charpentier, Diane Descamps, Charlène Martin, Fanny Lermechain, Jean-Christophe Plantier, Elodie Alessandri-Gradt   +8 more
doaj   +1 more source

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.

PLoS ONE, 2011
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and
C Preston Neff, Theresa Kurisu, Thomas Ndolo, Kami Fox, Ramesh Akkina   +4 more
doaj   +1 more source

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

PLoS ONE, 2014
ObjectivesRegimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens ...
Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper   +5 more
doaj   +1 more source

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients

HIV/AIDS: Research and Palliative Care, 2010
Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human ...
Thore Lorenzen
doaj  

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

PLoS Pathogens, 2016
Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remains ...
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae-Wook Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth   +18 more
doaj   +1 more source

Oral Presentation

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Computational investigations of potential inhibitors of monkeypox virus envelope protein E8 through molecular docking and molecular dynamics simulations

Scientific Reports
The World Health Organization (WHO) has declared the monkeypox outbreak a public health emergency, as there is no specific therapeutics for monkeypox virus (MPXV) disease. This study focused on docking various commercial drugs and plant-derived compounds
Rohit Das, Anil Bhattarai, Rohit Karn, Buddhiman Tamang   +3 more
doaj   +1 more source